Endothelial progenitor cells: Characterization, <Emphasis Type="Italic">in vitro</Emphasis> expansion,and prospects for autologous cell therapy |
| |
Authors: | D M Smadja A Cornet J Emmerich M Aiach " target="_blank">P Gaussem |
| |
Institution: | INSERM Unité 765, Paris, France. |
| |
Abstract: | Injection of hematopoietic stem cells or endothelial progenitor cells (EPCs) expanded ex vivo has been shown to augment neovascularization in adult patients, but the precise origin and identity of the cell population
responsible for these clinical benefits are controversial. The limited quantity of EPCs in the circulation has been the main
obstacle to clinical trials. Several authors have therefore attempted to expand these cells ex vivo in order to obtain a homogeneous cell therapy product. One possible means of expanding EPCs ex vivo is to activate the thrombin receptor PAR-1 with the specific peptide SFLLRN. Indeed, PAR-1 activation promotes cell proliferation
and C-X-C chemokine receptor type 4 (CXCR4) dependent migration and differentiation, with an overall angiogenic effect. This
review summarizes the results and rationale of clinical trials of angiogenic therapy, the nature of EPCs, the different methods
of ex vivo expansion, and current methods of quantification. |
| |
Keywords: | endothelial progenitor cells clinical trials expansion thrombin receptor PAR-1 SFLLRN peptide cell therapy |
本文献已被 PubMed SpringerLink 等数据库收录! |
|